GSK announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration FDA. In February 2024, the World Health Organization WHO recommended the removal of B/Yamagata strains from seasonal influenza vaccines… The WHO recommends that egg-based trivalent vaccines for the 2024-2025 northern hemisphere influenza season… In partnership with regulatory bodies, GSK worked quickly to ensure production, approval and availability of trivalent influenza vaccines with the recommended composition for the 2024-25 flu season. GSK expects to distribute over 36 million doses of its trivalent influenza vaccines in the US this season. Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months of age and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- iTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study
- GSK downgraded to Neutral from Buy at UBS
- FDA to evaluate potential risk of neural tube birth defects with dolutegravir
- GSK Acquires Key Vaccine Rights from Partner CureVac in €1.45B Deal